PD-1 Deep Dive: Lung Cancer Market Braced For Change
Execs speculated during third-quarter earnings calls about the impact of FDA approval for Merck's Keytruda in first-line lung cancer and looked forward to readouts of combination studies, which could soon bring another market shake-up.
You may also be interested in...
Few would argue that 2016 threw a number of curveballs into the global arena. With the New Year upon us, Scrip took a deep breath and asked a number of internal and external contributors across the pharma and biotech spectrum for their expectations for 2017.
At $920m, sales for Opdivo still overshadow competitors, but market dynamics are set to change with introduction of Merck's Keytruda in first-line lung cancer and Roche's Tecentriq in second-line lung.
The partial clinical hold placed on a combination trial of AstraZeneca’s PD-L1 inhibitor durvalumab and CTLA-4 inhibitor tremelimumab could be a portent of problems for Bristol-Myers Squibb’s PD-1/CTLA-4 combination trials – or it could be related to the head and neck cancer setting.